Medicine Information

Acetylcholinesterase Inhibitors (AChEIs)for the Treatment of Moderate and


Checklist of Treatments for Alzheimer's Disease

Part 1 of 8

For approximately ten years, I have cared for a parent with slowly advancing Alzheimer's disease. Contrary to all of the horror stories portrayed in the national media, I have found that the burden of caring for an Alzheimer's sufferer is less onerous than I originally expected. The primary reason that my burden has been lightened is that I give my mother a potent cocktail mix of drugs and vitamins to combat the disease. Her comparatively slow decline can be attributed to the efficacy of taking a multi-faceted approach to treating this incurable disease.

I subscribe to several news sources that provide daily updates on the latest reported findings and news about Alzheimer's drugs in development, the latest clinical trials, and treatments using over the counter vitamins and medications. Numerous people have asked me for advice on caring for a family member afflicted with Alzheimer's disease, and I have put together this checklist of therapies that should be administered daily to the Alzheimer's patient, unless there is clear and convincing evidence that an individual patient will have an adverse reaction to one of these medications.

At the outset, please note that wandering behavior is NOT normal for Alzheimer's patients; it is a sign of depression that can often be treated and corrected with an antidepressant. Diarrhea accidents and urine accidents are not normal for Alzheimer's patients, and again, these symptoms can be treated with readily available medications. Too many doctors are quick to jump to conclusions that every ailment afflicting an Alzheimer's patient is due to the disease. Any doctor who tells you that Alzheimer's patients normally wake up in the middle of the night, or sleep too much, or lose their appetites, and nothing can be done about it, should be fired. I am happy to debate the merits of my approach with anyone - medically qualified or not - who claims that there are only one or two classes of drugs available to treat Alzheimer's sufferers.

1. Acetylcholinesterase Inhibitors (AChEIs). A broad class of drugs inhibit the enzyme that breaks down the neurotransmitter, acetylcholine, in the brain. This class of drugs is fairly old as far as Alzheimer's therapies go; the first of these drugs became available in the 1995/96 period. One of the most popular of these drugs was also the second one in its class: donepezil HCL sold under the brand name "Aricept." Some newer drugs in this same class include galantamine hydrobromide, sold under the brand name Reminyl, and rivastigmine tartrate, sold under the brand name Exelon. In addition to being an AChEI, Reminyl also stimulates the nicotinic receptors, which means it should make a person more alert. We tried all three drugs and found Aricept worked best for my mother.

To make a long story short, Alzheimer's patients do not have enough of the chemical acetylcholine in their brains. Ideally, we would like to have a drug that generates new and abundant supplies of acetylcholine in the brain, but those drugs are still in development. As a second-best alternative, pharmaceutical firms developed drugs that would inhibit the body's natural enzyme that breaks down acetylcholine, thereby giving Alzheimer's patients a chance to maximize the use of what little acetylcholine is still produced in their brains.

Aricept, in the yellow 10 mg pills, has a long lasting effect and should be taken once a day. Reminyl is taken twice a day and has a shorter duration of efficacy. For whatever reasons, my mother responded better to Aricept than to Reminyl in terms of short term memory for completing daily functions, e.g., making her own breakfast. We could not detect any sign that Reminyl made her more alert. She began taking Aricept just months after it was approved by the FDA, which corresponded to the time she was originally diagnosed with Alzheimer's. A board-certified neurologist told us in 1997 it was best to take this drug at night, so that it could be dissolved in her system overnight and work at its peak when she awoke the next morning.

However, subsequent research has shown that all people need some breakdown of acetylcholine in their brains while sleeping to reach the deeper, more restful stages of sleep. Therefore, medical scientists now say that Aricept and other AChEIs should be taken in the morning, not at bedtime.

Contrary to news articles you may read, AChEIs are useful in the advanced stages of the disease, not just in the early stages. Even advanced-stage patients need as much acetylcholine as they can get. Some clinical studies are now underway to see whether the long-term, chronic consumption of AChEIs can slow the progression of Alzheimer's disease, even if they cannot stop the pathology of the disease.

Michael A. S. Guth, Ph.D., J.D., is a pharmaceutical economics researcher currently investigating treatments for Alzheimer's disease, hyperlipidemia, and osteoporosis / bone mineralization. More information about his research work is shown on his web page http://riskmgmt.biz/economist/pharmecon/pharmecon.htm. Utilizing a strong quantitative and statistical background, critique and discover the weakness in any medical study drawing statistical inferences from (clinical trial) data.


MORE RESOURCES:
This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news


The Conversation US

Why medicine leads the professions in suicide, and what we can do about it
The Conversation US
Earlier this month, one of us visited a prominent U.S. medical school to give a lecture on the topic of burnout and how physicians can find more fulfillment in the practice of medicine. Sadly, that very day, a fourth-year medical student there took her ...



New York Times

Using Medicine and Science to Improve the Quality of Life
New York Times
To Ms. Onie, that story offers an example of what is wrong with America's health care system: It can be so focused on medicine that it misses the social issues that really drive health. For more than 20 years since she co-founded the nonprofit Health ...



Forbes

RoosterBio Is Targeting $67 Billion Global Regenerative Medicine Market
Forbes
When you hear about “Regenerative Medicine,” it is often about stem cell therapy and tissue engineering. These two innovations alone are driving the large industry market estimates ranging from four billion dollars to $67 billion. The National ...



The Guardian

Mambas, medicine and one girl's race to survive Kenya's biting problem
The Guardian
In a country where snakebite treatment is costly, hard to come by and often inadequate, Rashid Chiti feared the worst when his daughter was bitten by a black mamba. Now the World Health Assembly is about to pass a resolution that might finally boost ...



Financial Times

Death's understudy: what sleep can teach medicine
Financial Times
The need to sleep is a bewildering habit of our species. As darkness falls, we undergo a nocturnal lapse in agency, a period of vulnerability during which the senses lie low and our guard falls. Even if we escape being burgled or murdered as we snooze ...



Lifehacker Australia

Your Baby's Teething Medicine Could Be Dangerous
Lifehacker Australia
If you're a parent, you've been there. All the rocking, patting and rounds of “Old McDonald” in the world won't stop your baby's misery. After weeks of sleepless nights, you think the child might need to be exorcised, but then it turns out she's just ...



HSC Newsbeat

Training to Provide a New Kind of Medicine
HSC Newsbeat
Your patients teach you a lot. As a young MD in a small Idaho town, David Rakel shared all on-call duties with another doctor at a 14-bed hospital. That situation, he says, spurned an interest in practicing medicine in a way that tries to find the root ...



STAT

The head of the National Cancer Institute on hopes for AI, the future of precision medicine, and big data
STAT
Nearly a year into his tenure at NCI, Sharpless sat down with STAT on Wednesday to talk about his new role, using artificial intelligence in cancer care, and how the NIH's “All of Us” precision medicine project could play into the NCI's big data ...



WHAG - www.localdvm.com

Local officials discuss breakthrough medicine and technology to combat disease
WHAG - www.localdvm.com
Regenerative medicine is a broad field that deals with gene and cell therapy or regrowing and the replacement of human tissue. “I'm highly confident that we have something that can cure HIV, but now, we have to prove it,” said Jeff Galvin, American ...



STAT

A focus on cost instead of value threatens the future of personalized medicine
STAT
ne size fits all never worked as a strategy for the fashion industry. Or the auto, furniture, and most other industries. It shouldn't be the strategy for medicine either, but unfortunately more often than not it is. And it may stay that way if the ...


Google News

home | site map | Dr. Thad Thomas
© 2006